These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 24945880)

  • 1. Interruption of cART in clinical practice is associated with an increase in the long-term risk of subsequent immunosuppression in HIV-1-infected children.
    Aupiais C; Faye A; Le Chenadec J; Rouzioux C; Bouallag N; Laurent C; Blanche S; Dollfus C; Warszawski J;
    Pediatr Infect Dis J; 2014 Dec; 33(12):1237-45. PubMed ID: 24945880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012.
    Cohen S; Smit C; van Rossum AM; Fraaij PL; Wolfs TF; Geelen SP; Schölvinck EH; Warris A; Scherpbier HJ; Pajkrt D;
    AIDS; 2013 Oct; 27(16):2567-75. PubMed ID: 23842124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.
    Soeters HM; Sawry S; Moultrie H; Rie AV
    J Acquir Immune Defic Syndr; 2014 Oct; 67(2):136-44. PubMed ID: 25072611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term consequences of treatment interruptions in chronically HIV-1-infected patients.
    Wolf E; Hoffmann C; Procaccianti M; Mosthaf F; Gersbacher E; Ulmer A; Karwat M; Brust J; Schuster D; Jaegel-Guedes E; Jaeger H
    Eur J Med Res; 2005 Feb; 10(2):56-62. PubMed ID: 15817423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4+ and viral load outcomes of antiretroviral therapy switch strategies after virologic failure of combination antiretroviral therapy in perinatally HIV-infected youth in the United States.
    Fairlie L; Karalius B; Patel K; van Dyke RB; Hazra R; Hernán MA; Siberry GK; Seage GR; Agwu A; Wiznia A;
    AIDS; 2015 Oct; 29(16):2109-19. PubMed ID: 26182197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensive five-drug antiretroviral therapy regimen versus standard triple-drug therapy during primary HIV-1 infection (OPTIPRIM-ANRS 147): a randomised, open-label, phase 3 trial.
    Chéret A; Nembot G; Mélard A; Lascoux C; Slama L; Miailhes P; Yeni P; Abel S; Avettand-Fenoel V; Venet A; Chaix ML; Molina JM; Katlama C; Goujard C; Tamalet C; Raffi F; Lafeuillade A; Reynes J; Ravaux I; Hoën B; Delfraissy JF; Meyer L; Rouzioux C;
    Lancet Infect Dis; 2015 Apr; 15(4):387-96. PubMed ID: 25701561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes in adolescents perinatally infected with HIV-1 and followed up since birth in the French perinatal cohort (EPF/ANRS CO10).
    Dollfus C; Le Chenadec J; Faye A; Blanche S; Briand N; Rouzioux C; Warszawski J
    Clin Infect Dis; 2010 Jul; 51(2):214-24. PubMed ID: 20536367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA.
    Rakhmanina N; Lam KS; Hern J; Young HA; Walters A; Castel AD
    J Int AIDS Soc; 2016; 19(1):20936. PubMed ID: 27797320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
    Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
    HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
    Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
    Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of anti-retroviral treatment in HIV-infected orphans and non-orphans at an ART centre in North India.
    Bhattacharya M; Saxena R
    Paediatr Int Child Health; 2012; 32(4):228-32. PubMed ID: 23164297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Change in absolute CD4 count with antiretroviral treatment in resource limited setting: a retrospective cohort study in children in Ethiopia.
    Berhan Y
    Ethiop Med J; 2011 Oct; 49(4):289-98. PubMed ID: 23409394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing HIV-1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy.
    Chaix ML; Seng R; Frange P; Tran L; Avettand-Fenoël V; Ghosn J; Reynes J; Yazdanpanah Y; Raffi F; Goujard C; Rouzioux C; Meyer L;
    Clin Infect Dis; 2013 Mar; 56(6):880-7. PubMed ID: 23223603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment interruption for virological failure or as sparing regimen in children with chronic HIV-1 infection.
    Monpoux F; Tricoire J; Lalande M; Reliquet V; Bebin B; Thuret I
    AIDS; 2004 Dec; 18(18):2401-9. PubMed ID: 15622316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France.
    de Monteynard LA; Matheron S; Gilquin J; Pavie J; de Truchis P; Grabar S; Launay O; Meynard JL; Khuong-Josses MA; Rey D; Simon A; Mahamat A; Dray-Spira R; Costagliola D; Abgrall S;
    AIDS; 2016 Sep; 30(14):2235-46. PubMed ID: 27428741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for extended age dependent maternal immunity in infected children: mother to child transmission of HIV infection and potential interventions including sulfatides of the human fetal adnexa and complementary or alternative medicines.
    Bhargav H; Huilgol V; Metri K; Sundell IB; Tripathi S; Ramagouda N; Jadhav M; Raghuram N; Ramarao NH; Koka PS
    J Stem Cells; 2012; 7(3):127-53. PubMed ID: 23619381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structured interruptions of highly active antiretroviral therapy in cycles of 4 weeks off/12 weeks on therapy in children having a chronically undetectable viral load cause progressively smaller viral rebounds.
    Palacios GC; Sanchez LM; Briones E; Ramirez TJ; Castillo H; Rivera LG; Vazquez CA; Rodriguez-Padilla C; Holodniy M
    Int J Infect Dis; 2010 Jan; 14(1):e34-40. PubMed ID: 19467895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.